Recent clinical studies indicate that adoptive T-cell therapy and especially chimeric antigen receptor (CAR) T-cell therapy is a very potent and potentially curative treatment for B-lineage hematologic malignancies. Currently, autologous peripheral blood T cells are used for adoptive T-cell therapy. Adoptive T cells derived from healthy allogeneic donors may have several advantages; however, the expected occurrence of graft versus host disease (GvHD) as a consequence of the diverse allogeneic T-cell receptor (TCR) repertoire expressed by these cells compromises this approach. Here, we generated T cells from cord blood hematopoietic progenitor cells (HPCs) that were transduced to express an antigen receptor (AR): either a CAR or a TCR with or without built-in CD28 co-stimulatory domains. These AR-transgenic HPCs were culture-expanded on an OP9-DL1 feeder layer and subsequently differentiated to CD5 C CD7 C Tlineage precursors, to CD4 C CD8 C double positive cells and finally to mature AR C T cells. The AR C T cells were largely naive CD45RA C CD62L
Introduction
Adoptive transfer of gene-modified T cells expressing either chimeric antigen receptors (CARs) or tumor-specific T-cell receptors (TCRs) constitutes a novel and, under certain conditions, a highly effective strategy to treat malignancies.
Clinical trials involving CAR T-cell therapy have demonstrated impressive clinical responses in CD19
C acute lymphoblastic leukemia with reported complete remission rate of about 90%. [1] [2] [3] CARs are artificial modular proteins consisting of a single chain variable fragment for antigen recognition, a spacer, a transmembrane region and one or more intracellular functional sequences derived from CD3z and co-stimulatory molecules such as CD137 or CD28. 4 First-generation CARs carry only the CD3z intracellular sequence. First-generation CAR T cells however do not display potent antitumoral responses in vivo. Second-generation CAR T cells have besides CD3z also a costimulatory domain that prevents the development of anergy and increases interleukin-2 (IL-2) production upon antigenic stimulation. 5 All clinical trials that reported high rates of clinical responses involved second-generation CAR T cells with either CD28 or CD137 as co-stimulation.
TCR transgenic T cells directed to tumor antigens such as NY-ESO-1 and MART1 have also entered clinical trial to study their efficacy in melanoma, sarcoma and multiple myeloma. 6, 7 Clinical TCR gene therapy studies may be challenged by (1) low affinity of the receptor (directed towards autoantigens), (2) interference of the endogenous TCR with the expression of the transgenic TCR either by cross-pairing of the TCRa and TCRb chains or by competition for CD3, [8] [9] [10] [11] [12] [13] (3) the generation of graft versus host disease (GvHD) 13 and/or (4) the lack of co-stimulation. 14 Several strategies have been reported to address these challenges such as increasing affinity of the TCR, preventing cross-pairing by introducing cysteine residues in the transgenic TCR chains, by gene editing the endogenous TCR loci or, similar to CARs, by inclusion of CD3z and CD28 sequences in the TCRa and TCRb construct (TCR with built-in co-stimulation). 8, 9, [15] [16] [17] [18] [19] [20] In some malignancies, CAR T cells seem to be less potent to eradicate the tumor than in others. For instance, CD19 CAR T cells seem to be less efficient in non-Hodgkin lymphoma than in acute lymphoblastic leukemia. 21 In addition, the effectiveness seems to be dependent on the intensity of the conditioning regimen, suggesting that concomitant chemotherapy acts synergistically due to the added antitumoral effect and/or due to the immune suppressive effect that inhibits anti-CAR T-cell immune responses by the patient. 1, 2, 22 These data suggest that for some malignancies, CAR T-cell therapy should be combined with other therapeutic regimens to increase cure rate. One possibility is to combine antigen receptor (AR) T-cell therapy with allogeneic stem cell transplantation and/or chemotherapy. Directing allogeneic T cell toward defined cancer antigens, while at the same time avoiding the toxicity of these T lymphocytes caused by alloreactivity of the polyclonal TCR repertoire, may provide a very potent and safe therapy in combination with chemotherapy. For these reasons, it could be beneficial to generate AR C T cells from allogeneic sources such as banked cord blood or from adult allogeneic donors. [23] [24] [25] To prevent GvHD, expression of the endogenous TCRs by the peripheral blood T cells should be suppressed to generate mono-specific CAR or TCRtransgenic T cells. Various methods have been described to accomplish this, mostly based on the targeting of the Ca of the TCR locus either by gene editing or siRNAs. 15, 26 We previously reported that mono-specific TCR-transgenic cells lacking endogenous rearrangements can be generated from cord blood hematopoietic progenitor cells (HPCs) . 27 This method is based on allelic exclusion, a phenomenon that occurs physiologically in the thymus and that ensures that each T cell successfully rearranges only a single TCRb locus. Because of allelic exclusion, T cells generated from TCR-transgenic HPCs do not rearrange endogenous TCR loci and T cells that are generated are mono-specific and express only the transgenic TCR. This strategy involves transduction of HPCs to express a tumor-specific TCR and subsequent differentiation of the HPCs to T cells on OP9 feeder cells in the presence of cytokines and Notch stimulation.
Here, we have investigated whether CARs and TCRs with or without built-in CD28 co-stimulatory domain could inhibit rearrangements of endogenous TCR loci while at the same time allow the generation of functional transgenic AR C , tumor-specific T cells. In addition, we assessed whether cells expressing ARs with built-in CD28 co-stimulation acquired more potent T-cell functional capacity. We observed that very potent functional T cells can be generated using this strategy and that these cells express the transgenic CAR or TCR in the virtual absence of rearranged endogenous TCR loci. These cells are therefore assumed to be devoid of alloreactivity.
Results

Antigen receptor transgenic CD34
C HPCs differentiate to mature T cells on OP9-DL1 feeder cells
Human T-lineage committed CD34
C HPCs either isolated directly from thymus or generated in vitro from cord blood
CD34
C cells were transduced to express a "second-generation" carcino-embryonic antigen (CEA)-specific CAR carrying an intracellular CD3 z-chain signaling sequence and the transmembrane and co-stimulatory CD28 intracellular signaling sequence (CAR:28z) (Fig. S1 ). Twenty to sixty percent of the cells expressed the CAR and the co-transduced GFP after transduction. Transduced GFP C and untransduced GFP ¡ cells were subsequently cultured together on OP9-DL1 feeder cells for 25 d in the presence of growth factors to obtain CAR C T cells (Fig. 1A) . Compared to untransduced cells, the percentages of immature CD4 C (7.2% vs 13.6%) and CD4 C CD8 C double positive (DP) (51.9% vs 64.2%) cells were consistently reduced in the GFP C CAR transgenic population due to a prominent population of mature CD27 C CD1a ¡ cells, which were virtually all double negative (DN) or CD8 C (not shown), in the CAR transgenic cells whereas only few mature CD27
C
CD1a
¡ cells were present in untransduced cultures (45.3% vs 2.6%).
We have shown previously that, in untransduced OP9-DL1 cultures, mature T cells are mainly TCRgd C cells. 28 In addition, we have shown that in cultures initiated with HPCs transduced to express a TCRab, mature CD27
C
CD1a
¡ T cells are virtually absent, but addition of the agonist peptide in the presence of the restricting HLA antigen induces maturation. 27 Here, antigen-dependent maturation is unlikely as CEA expression analysis on these cultures with qPCR was consistently negative (data not shown). Subsequently, we investigated whether CD28 co-stimulatory signals may be inducing terminal maturation in the absence of ligand. Cultures transgenic for a "first-generation" CAR containing only the transmembrane and intracellular CD3z-chain signaling sequence (further referred as CAR:z) and cultures transgenic for the second-generation CAR containing the transmembrane and intracellular CD28 signaling sequence as well as the intracellular CD3z-chain signaling sequence (CAR:28z), both specific for CEA, were compared side by side (Fig. 1B) . The percentage of DPs of the GFP C CAR transgenic cells was higher in the CAR:z transduced cells compared to the CAR:28z transduced cells (45.2% vs 33.5% at day 14, 63.5% vs 36.8% at day 25). At the same time, the level of antigenindependent maturation as evidenced by the presence of mature CD27 C CD1a ¡ cells was lower in the CAR:z transgenic cells compared to the CAR:28z transgenic cultures (2.1% vs 11.3% at day 14, 10.3% vs 36.0% at day 25). These differences were not caused by a co-stimulator-induced acceleration of T-cell differentiation as this phenomenon was observed in early (day 14) as well as in late (day 25) cultures. We hypothesized that the number of CAR molecules per cell may impact the signaling strength. Accordingly, the CAR:z was expressed to a lower degree than the CAR:28z, while the transduced cells expressed the same GFP levels (Fig. 1C) . To exclude that differences in antigen-independent maturation of the different transgenic cells was caused by differential expression levels of the CAR rather than the costimulatory properties and/or the transmembrane domain of the CAR, we stained the different CARs directly with antihuman IgG1 antibody, which binds to the extracellular spacer of the CAR, and compared percentages of DPs and of mature cells for both transgenic cells. For cells with the same expression levels of the AR, a decreased percentage of DPs (48.6% vs 60.8% and 28.9% vs 60.0%) and an increased percentage of antigen-independent maturation (32.4% vs 8.6% and 37.5% vs 16.6%) were noted in CAR:28z C cells vs CAR:z C cells. AR expression levels also contributed, with high AR-expressing cells maturing at higher frequencies than low AR-expressing cells (16.6% vs 8.6% and 37.5% vs 32.4%). We conclude that phenotypically mature T cells are generated from CAR transgenic cells in a ligand-independent manner and that the efficiency of maturation is dependent on the levels of AR expression and on the presence of costimulatory domain and/or the nature of the transmembrane domain in the AR.
In addition, the dimerized CD3z intracellular domain of the first-generation CAR:z itself seems to induce a prominent antigen-independent maturation ( Fig. 1D and E) . To further substantiate this, we generated modular receptors from a cloned TCR similar to CARs. Both the a and the b chains of a wildtype (wt) HLA-A2 restricted TCR specific for gp100 were linked with the intracellular domain of the CD3z only (TCR:z) or in addition to the CD28 co-stimulatory domain (TCR:28z) (Fig. S1 ). HPCs transgenic for the wtTCR, for the TCR:z and the TCR:28z were identified by positive staining for Vb (Fig. 1D) . wtTCR transgenic cells generated only a low percentage of mature T cells in the absence of the TCR ligand, as expected (1.1%). In contrast to first-generation CARs, we did not observe increased ligand-independent maturation of the TCR:z transgenic cultures (1.4%) compared to wtTCR. However, when a co-stimulatory CD28 domain was included in the TCR, we did observe an increased efficiency of ligand-independent maturation (6.0%). As previously described, 27 addition of the TCR cognate peptide further increased maturation of the wtTCR transgenic cells to mature CD27
C
CD1a
¡ T cells (28.0%). This was also the case for the TCR:z and TCR:z:28 transgenic cells (62.6% and 80.9%, respectively) ( Fig. 1E ). In conclusion, wtTCR and TCR with incorporated CD3z required specific ligand to drive maturation of the T cells, whereas TCR with incorporated CD28 transmembrane and co-stimulatory domain induced antigen-independent maturation of T-cell precursors which can be further enhanced by addition of ligand.
Since DP cells are highly proliferative cells in culture, we asked whether premature ligand-independent maturation of the precursor cells impacts cell expansion in OP9-DL1 cultures of cells transgenic for ARs with built-in CD28 sequence. In Fig. 2A , expansion after CAR transduction is presented. Consistent with the lower levels of DP cells observed in CAR:28z transgenic cells, total expansion of these cells was lower than that of first-generation CAR:z transgenic cells (670-vs 1361-fold increase for CAR:28z and CAR:z AR-transgenic cultures, respectively, on day 19). Although the total number of cells and the number of DPs that were obtained for TCR:28z-transgenic cells were significantly lower, the number of CD27
C
CD1a
¡ mature T cells obtained from these cultures tended to be higher mainly due to late generation and/or expansion of mature T cells (388-vs 134-fold CAR:28z and CAR:z AR-transgenic cultures, respectively, on day 25). Similar expansion rates were observed for the TCR constructs (Fig. 2B) . T-lineage committed HPCs transgenic for wtTCR expanded early together with the generation of DP cells, but a few mature cells are generated without agonist stimulation. TCR:z transgenic cells generated comparable cell numbers but more CD27 C CD1a ¡ mature T cells were generated. Cultures transgenic for TCR:28z displayed reduced early proliferation due to defective DP generation; however, at later stage more CD27 C CD1a ¡ mature T cells were generated, suggesting that co-stimulatory signaling induces longer survival or proliferation of mature T cells in vitro. In all cases, total cell expansion starting from fresh CD34
C HPCs is substantial (Fig. 2C ). After initial culture on OP9-DL1 for 10-14 d, the T-lineage committed cells are transduced and further cultured on OP9-DL1 for additional 28-35 d. Total expansion rates were 1.56£10
4 times for first-generation CAR:z transgenic cells compared to 5.23£10 3 for cultures with second-generation CAR:28z. In conclusion, AR-transgenic HPCs from cord blood can be expanded more than 1000-fold and differentiated in OP9-DL1 cultures to mature cells. Unlike wtTCR transgenic HPCs, AR transgenic cells with build-in CD28 co-stimulator sequence did not require antigen for expansion.
AR-transgenic CD34
C HPCs generate AR C T cells that lack CD3 membrane expression Since CARs do not require CD3 for membrane expression, we checked whether the cells generated in these cultures had TCR/CD3 complexes expressed on the membrane. In Fig. 3A , it is shown that >7% of the untransduced GFP ¡ cells express CD3 in combination with either a TCRab or a TCRgd receptor. In contrast, the GFP C CAR transgenic cells in the same cultures are largely CD3 negative, despite the presence of a higher percentage of mature CD27 C CD1a ¡ cells (Fig. 1 ). This was the case for both CAR:z and CAR:28z transgenic cultures. A similar phenomenon was observed in TCR-transgenic cultures (Fig. 3B ). wtTCR transgenic cells expressed CD3 as well as the transgenic TCR, as evidenced by the Vb14 expression. In contrast, Vb14-expressing TCR:z and TCR:28z transgenic cells expressed the AR in the absence of CD3 membrane expression 16, 20 . These transgenic cells expressed no CD3. A small population of Vb14 C cells expressed CD3, but these are most likely untransduced cells that have rearranged the endogenous TCR at the Vb14 gene segment. To exclude that the CD3/TCR complex was not expressed on the membrane of CAR-transgenic T cells due to the absence of CD3 protein expression, we performed cytoplasmic CD3e staining. Fig. 3C shows that cCD3 was present at high levels in the cytoplasm, but not on the cell surface (sCD3), which is likely due to the absence of rearranged endogenous TCRs rather than due to the non-T-cell nature of the cells. Cytoplasmic expression of CD3 suggests that the CAR C , TCR/CD3 ¡ cells are bona fide T cells. However, natural killer (NK) cells generated from cord blood on OP9-DL1 feeder cells may also express cytoplasmic CD3. 29 We therefore analyzed the mature CAR C cells for other T and NK-lineage markers. The CAR transgenic cells were positive for CD5, CD7 and CD2 (Fig. 3D) . The combination of these three markers is exclusively expressed by T cells, whereas NK cells are consistently CD5 
CD56
C cells, the CAR C cells generated in vitro were to a large degree negative for the NK cell marker CD56. Only a minor population of the cells was CD56 C , a marker that is also present on activated T cells. NKG2D, a marker for both NK cells and mature CD8
C single positive T cells, was expressed on these cells.
To further substantiate the T-cell nature of the CAR C CD3 ¡ cells, we initiated an OP9-DL1 culture with a pure population (>99%) of CD34 C cord blood cells (Fig. 3E) . Thirteen days later, the T-cell lineage committed CD5 C
CD7
C cells were again sorted to homogeneity (>99% purity), transduced and put back in culture to obtain mature T cells. Another 8 d later, GFP C CAR C DP cells as well as GFP C CAR C CD27 C CD1a ¡ mature cells were generated from these cultures, indicating that the CAR C mature cells were efficiently generated from CD5 C
C T-lineage precursors and therefore are T lineage cells despite the absence of membrane CD3 expression. We therefore conclude that the CAR C CD3 ¡ cells represent mature T cells. The CAR C mature T cells were heterogeneous with respect to CD45RA/CD45RO expression (Fig. 3D) . However, most cultures generated a large population of CD62L C CD45RA C CD45RO ¡ cells, indicating that the generated T cells have a naive T-cell phenotype (Fig. 3F) . As expected, the CAR T-cell populations did not contain CD4 C T cells. Most CAR C cells were either double negative (DN) or expressed CD8a and CD8b, similar to the reported phenotype of TCRab transgenic T cells generated on OP9-DL1 feeder cells.
CD34
C HPC derived transgenic AR C T cells lack endogenous TCRa and TCRb rearrangements
We previously reported that transgenic expression of a wtTCRab in HPCs completely suppresses rearrangements of the endogenous TCRb locus and that agonist selection by TCR stimulation suppresses rearrangements of the endogenous TCRa locus, resulting in mature T cells that express only the transgenic TCR. 27 . In line with this, we showed evidence in the previous section that the CAR:z, CAR:28z, TCR:z and TCR:28z expressing cells were CD3 negative, suggesting the absence of endogenous rearrangements of the TCR loci. To further substantiate the absence of endogenous rearrangements, we measured mRNA levels coding for the different components of the CD3/TCR complex in the (TCR-negative) CAR transgenic HPC-derived cell lines. Transcripts encoding CD3g, CD3d, CD3e and CD3z were detected, whereas TCRa and TCRb transcripts were selectively lacking in the HPC-derived cell lines (Fig. 4A) . Next, we analyzed whether a second transduction to express a transgenic (CMV-specific) wtTCRa or a wtTCRb chain or both could induce membrane expression of the CD3 complex in TCR:z and TCR:28z transgenic HPC-derived cell lines. As expected, when both wtTCR chains were introduced, membrane CD3 expression was observed in both cell lines, indicating that all components required for TCR expression were present. However, introduction of only the TCRa chain failed to induce membrane CD3 expression, indicating that no endogenous TCRb chains were expressed. About 0.9-1.2% of the cells expressed CD3 upon transgenic TCRb introduction, indicating, as previously reported, that low levels of early TCRa rearrangements may occur during the DP differentiation stage. 27 Finally, we studied endogenous rearrangements by highthroughput sequencing of PCR-amplified complementary determining region (CDR3) RNA. Whereas CAR:28z transgenic PBMC derived cell line showed a normal distribution of in frame CDR3 lengths, the HPC-derived ARC cell lines show virtually no endogenous TCRb rearrangements and severely reduced TCRa rearrangements (Fig. 4C) . These data show that expression of a CAR, similar to a TCRab, suppresses endogenous rearrangements to a large degree leading to single receptor AR C CD3/TCR ¡ cells.
CD34 C HPC-derived transgenic AR C T cells display specific antitumor activity
We analyzed whether the in vitro generated AR C CD8 C and double DN T cells displayed the characteristic functional capacities of T cells, i.e., cytokine release and specific cytotoxicity towards cognate target cells. The in vitro generated mature T cells were expanded for one cycle on feeder cells in the presence of IL-7 and IL-15 and subsequently assessed for specific activity. To exclude the effects of the few CD3 C cells present in these cultures, cells were sorted for GFP C
CD3
¡ cells. Specific killing by the CAR C T cells was tested using the CEA ¡ Colo320 and the CEA C LS174T tumor cell lines as targets. As shown in Fig. 5A , in vitro generated T-cell lines transgenic for CAR:z and CAR:28z constructs killed the CEA C tumor cells specifically to a similar degree. Killing was specific and largely mediated by the CAR since CEA C tumor cell lines cells were killed much more efficiently than CEA ¡ tumor cell lines (Fig. S2 ). To compare killing activity to peripheral blood derived T cells, killing by the CAR:28z transgenic in vitro generated T cells was assessed side by side with CAR:28z transgenic sorted CD4
C and CD8 C T cells. Fig. 5B shows that whereas peripheral blood derived CD4 C T cells kill tumor cells only marginally, peripheral blood derived CD8 C T cells and in vitro generated T cells vigorously kill CEA C LST174T cells, indicating that the in vitro generated CD8 C and DN T cells have similar cytotoxic activity as have conventional CD8
C T cells. Finally, we compared killing by wtTCR-transgenic, single AR C T cells to TCR:z and TCR:28z transgenic, single AR C T cells: again killing activity was similar, independent of the nature of the TCR that was expressed, on T2 targets loaded with the gp100 peptide as well as on the gp100 expressing tumor cells (Figs. 5C and S3) .
To test for cytokine production, the cells were stimulated and subsequently analyzed for intracellular IFNg, TNFa and IL-2 production by flow cytometry. We tested for IFNg and TNFa, cytokines that are produced by NK cells as well as CD4
C and CD8 C T cells and for IL-2, a cytokine produced at high levels by peripheral blood CD4 C T cells, to a lesser extent by peripheral blood CD8 C T cells and not at all by NK cells. Maximal stimulation with PMA and ionomycin of the CARtransgenic T cells demonstrated that virtually all cells of both T-cell lines were able to secrete simultaneously all three cytokines (Fig. 5D) . When stimulated by plate bound anti-IgG1 antibody, CAR:z-transgenic cells produced consistently lower levels of cytokines and a consistently lower fraction of cells coproduced two cytokines (8.7 and 5.6% vs 32.8% and 25.7%) compared to CAR:28z-transgenic cells, which is in line with the previous reports. 5 Specific cytokine production was assessed after stimulation with the CEA ¡ Colo320 and the CEA C LS174T tumor cells. Although there was some background IFNg secretion that is AR-independent by 5-10% of the cells, upon specific CAR engagement, T cells secreting all three cytokines are observed only after stimulation with the CEA C cell line LST174T cells. This is especially the case for the CAR:28z-transgenic cells.
Finally, we compared specific cytokines secretion by in vitro generated wtTCR transgenic T cells with TCR:z and TCR:28z-transgenic T cells (Fig. 5E ). After specific gp100 peptide addition to T2 HLA-A2
C antigen presenting cells, the levels of all three cytokines were increased. Similar to the CAR transgenic cells, the TCR:28z transgenic T cells with built-in CD28 costimulatory domain demonstrated higher numbers of cells that produced two cytokines compared to wt or TCR:z transgenic cells (13.2% and 30.8% for TCR:28z vs 1.7% and 7.0% for wtTCR and 4.7% and 15.0% for TCR:z). This was the case upon stimulation with T2-gp100 peptide as well as upon coincubation with gp100
C cell lines FM3. In conclusion, in vitro CD34
C derived T cells, in particular when transgenic for an AR with build-in CD28 co-stimulatory domain, are highly cytotoxic and cytokine producing cells despite their CD8
C or DN phenotype. These cells are CD3 negative, mono-specific T cells that produce high levels of IL-2 and IFNg upon specific stimulation discriminating these cells from NK cells.
Discussion
We demonstrated that CAR or TCR expressing T cells can be generated from cord blood HPCs in vitro. Importantly, CARs as well as TCRs block the endogenous rearrangements of the TCRa and TCRb locus resulting in mono-specific T cells since they express only the transgenic AR and lack the endogenous TCR. In addition, we showed that these T cells are very potent in cytokine production as well as cytotoxicity especially when CAR or TCR-constructs are linked to the CD28 co-stimulation signal. Importantly, the CD28 co-stimulation signal does not compromise T-lineage differentiation and the development of functional T cells from HPC.
By transducing CD34 C HPCs, which we subsequently differentiated upon OP9-DL1 feeder cells, we took advantage of the phenomenon of allelic exclusion to generate mono-specific, transgenic ARC T-cell populations that do not express a polyclonal, endogenous TCR repertoire as is the case with transgenic peripheral blood T cells. It has been shown in TCR-transgenic mice, that rearrangement at the TCRb locus are completely blocked, whereas the TCRa rearrangements are reduced. 30 TCRa rearrangements are operative during the DP stage in the thymus and are terminated by positive selection. In humans, TCRb locus rearrangements are suppressed in TCR-transduced HPCs which were transplanted in humanized mice, as well as in T cell derived from iPSC generated from a T-cell clone. [31] [32] [33] [34] We have shown that also in OP9-DL1 cultures TCRb rearrangements are blocked and that TCRa rearrangements can be largely prevented by early agonist selection, thereby reducing the length of the DP stage. 27 Since TCR:28z-transgenic cells already mature spontaneously, it is not surprising that these cells rapidly pass through the DP stage and that TCRa rearrangements are severely reduced. As shown in this report, also CARs potently block TCR locus rearrangements to the extent that virtually no TCR/CD3 expressing cells are generated. The observation is in line with a previous report that CAR-transgenic iPSC-derived T cells have a reduced TCR repertoire, however these iPSC cells were derived from a T-cell clone. 35 As the T-cell clone has rearranged TCRb and TCRa locus, it is not unexpected that de novo rearrangements were inhibited and the issue whether this was caused by the CAR or by the pre-TCR was not addressed. A report by Zakrzewski et al. using transfer of murine CD19-CAR-transgenic T-cell precursors in mice reported no effect of the first generation CAR on the development of the TCRb repertoire, nor on the expression of CD4 C , CD8
C and CD3. 36 However, in a recent study, HIVspecific CAR-transduced human HPCs injected in BLT mice resulted in a reduced number of CD3 positive cells in the thymus and the TRECs per cell were decreased, indicating that TCR rearrangements were blocked. 37 The latter data in concert with the data presented here strongly suggest that also CARs block rearrangements during T-cell development in vivo as well as in vitro with the result that mono-specific T cells are generated. Discrepant results could be explained by the expression level of the CAR in the thymus as we have shown that low expression affects Tcell differentiation to a lesser degree. As expression of certain promoters such as CMV promoters are shut down in the thymus this may explain the discrepant results in the in vivo studies.
Alternative methods to generate mono-specific T cells without expression of the endogenous TCR, using gene editing of peripheral blood T cells, have limitations. Gene editing methods can be applied to CAR T cells as one TCR-chain can be edited and by subsequent screening for CD3
¡ CAR C cells, CD3/TCR negative CAR T cells can be isolated also from peripheral blood. However, for TCR transgenic T cells, this method is more cumbersome, as both chains have to be eliminated to prevent cross-pairing. In addition, this requires lengthy screening, which may not be practical in a clinical setting. 15 Furthermore, gene editing has its own pitfalls, in particular off-target mutations which may prove to be oncogenic depending on the targeted sequence involved.
The absence of endogenous TCRs has several advantages for adoptive cell therapy. Interference with expression of the tumor-specific TCR is minimized due to the expected absence of cross-pairing. Cross-pairing may induce unexpected autoreactivity and GvHD as well as reduce the expression levels of the transgenic TCR. 13, 16 In the approach described here, additional measures were taken to prevent interference with the tumor-specific TCR expression: The linked CD3z and CD28 signaling sequences force both transgenic chains to preferentially pair with each other and not with endogenous chains. 17, 20 In addition, as these TCRs are surface-expressed independent of CD3, there is no competition for endogenous CD3 as the cytoplasm brightly stains for superfluous CD3 that cannot incorporate into the membrane due to lack of a TCR.
The CD28 co-stimulatory signal may not only prevent the development of anergy, but may also significantly increase survival and proliferation of these cells upon antigen stimulation. 17 Here, we show that the mature CD27 C CD1a ¡ cells survive and/ or proliferate much better in the OP9-DL1 cultures compared to AR C cells without co-stimulatory signal and we show that these cells produce higher levels of cytokines including IL-2. The high levels of cytotoxic activity together with polycytokine secreting capabilities, despite their DN or CD8
C phenotype, make these cells good candidates for a redirected cell therapy of cancer. A limitation of this study is the lack of proof of in vivo functionality. Preliminary in vivo data suggest that these cells require human IL-15 for survival and experiments with human IL-15 transgenic mice are now being set up.
Two groups reported rejuvenation of T cells by generating iPSCs from T-cell clones and subsequent differentiation to T cells. 33, 34, 38 These authors report that they obtain CD62LC CD45RAC T cells and that these T cells may have again become naive, conventional T cells. As the cells they describe are in many respects similar to the T cells derived here from HPCs, data underline their potential value in cell therapy.
The mono-specific AR C T cells can be applied in several ways in cancer therapy. Similar to allogeneic virus-specific T cells that are administered to patients after bone marrow transplantation, one can generate a bank of common HLA-expressing, cord blood HPC-derived allogeneic CAR T cells. In this way, partially matched CAR T cells can be administered to post-transplant patient. Using this approach, CMV-specific T cells induce remission of CMV disease. 39 Whether such an approach would also work for CAR T cells in treatment of malignancies is unclear, as it has been shown that survival of CAR T cells for at least 6 mo is required for cure. 3 Alternatively, allogeneic CAR therapy could be combined with heavy immunosuppressive conditioning. This conditioning will work in synergy with CAR T cells on the tumor and at the same time will prevent anti-CAR T cell alloresponses and anti-CAR responses, thus allowing the cells to survive longer. In the most intensive therapy, the latter could be combined with T-cell depleted stem cell therapy, either using HLA matched cord blood or adult mobilized blood cells. In these cases, stem cell chimerism will induce lifelong tolerance sustaining survival of the donor CAR T cells. In all these instances, CAR T cells can be generated from healthy donor material, under optimal conditions and sufficiently in numbers in advance for a broad cohort of patients.
Materials and methods
Isolation of human cells
Postnatal thymus (0-12 y of age) and cord blood were obtained and used following guidelines of the Medical Ethical Committee of the Ghent University Hospital (Belgium). Informed consent was obtained in accordance with the Declaration of Helsinki (Ethics Committee UZ Ghent decision B670201215078). Human T-lineage committed CD34
C cells were isolated from postnatal thymus and CD34 C HPCs were isolated from cord blood by magnetic activated cell separation (MACS, Miltenyi, cat# 130-046-703). Cord blood CD34
C cells were subsequently T-lineage committed by culture on OP9-DL1 in the presence of 50 ng/mL SCF, 20 ng/mL Flt3L and 10 ng/mL IL7 for 12-14 d. Purities were usually > 90%.
LST174T (ATCC CCL 188) and H508 (ATCC CCL 253) are CEA-expressing carcinoma cell lines, Colo320 (ATCC CCL 220), Colo201 (ATCC CCL 224) and H716 (ATCC CCL251) are CEA ¡ colon carcinoma cell lines, FM3, MEL624 and MEL526 are HLA-A2
C melanoma cell lines expressing gp100 obtained from R Debets. JY is a human HLA-A2 C B cell line and Jurkat is a CD3 C leukemic line. These cell lines were maintained under standard culture conditions.
Production of retroviral vectors
The different construct used are represented in Fig. S1 . The carcino-embryonic antigen (CEA)-specific CAR:z and CAR:28z constructs 5, 40 were transferred into the LZRS IRES eGFP (LIE) vector using XhoI and BglII and viral particles were produced using the Phoenix packaging cell line. Retroviral supernatans were collected at day 14 after transfection and hygromycin selection and frozen until use. Transduced cells were detected either by eGFP expression or by an anti-IgG antibody directed against the human IgG1 spacer domain present in the extracellular domain of both CARs.
The TCR constructs were generated from a gp100-specific (epitope: YLEPGPVTA) HLA-A2 restricted receptor using TRBV14s1. 16, 17, 41 The TCR:z was constructed by linking the extracellular part of both the wt TCRa and TCRb chain to the full length transmembrane and intracellular parts of CD3z. 16, 42 The TCR:28z was constructed by linking the extracellular part of both the wt TCRa and TCRb chain to the CD28-CD3z tail described above (kindly provided by H. Abken, Cologne, Germany) (Fig. S1) . 20 wtTCR, the TCR:z and the TCR:28z cDNAs were cloned into pBullet retroviral vectors. VSV-G envelope-pseudotyped Moloney murine leukemia virus retroviral particles that contain TCR RNAs were freshly produced by a co-culture of the packaging cells 293T and Phoenix-A following calcium phosphate transfections and were used fresh. wtTCR, the TCR:z and the TCR:28z were detected by a Vb14-specific antibody (Beckman Coulter, cat# PN IM2047).
Retroviral transduction
Fresh thymic CD34
C were pre-activated for 1 d in the presence of cytokines (5 ng/mL SCF and 10 ng/mL IL7). CD34
C CB cells were transduced after T-lineage committment (see above) in the presence of SCF (5 ng/mL, PeproTech, 300-07)), Flt-3L (10 ng/mL, PeproTech 300-19) and IL-7 (10 ng/mL, R&D Systems, 207-IL). Transduction efficiencies varied but were usually between 20% and 60% for the CAR-transgenic cells, and between 2% and 8% for the TCR transgenic cells. Unless stated otherwise, the mixture of transduced and untransduced cells was cultured without prior Fluorescent Activated Cell Sorting (FACS) on OP9-DL1 cells.
OP9-DL1 co-cultures
Transduced cells were co-cultured on a subconfluent OP9-DL1 cell layer in a-MEM medium (Gibco, 22561-021) supplemented with 20% FBS (Bovogen, SFBS), 2 mM L-glutamine, 100 IU/mL penicillin, 100 IU/mL streptomycin, 5 ng/mL SCF, 10 ng/mL Flt3L and 10 ng/mL Il-7, as described previously. 43 
Agonist peptide stimulation
Cells were harvested from OP9-DL1 and were, either as such or after FACS sorting for immature DP cells, seeded in tissue culture plates (BD Biosciences) in complete IMDM in the presence of 10 ng/mL IL-7 for 7 d. The gp100 YLEPGPVTA peptide and, as irrelevant control, influenza matrix protein M1 [58] [59] [60] [61] [62] [63] [64] [65] [66] peptide were used (Anaspec by Eurogentec). For the CAR experiment, a CEA-expressing adherent cell line (LST174T) was added to the cultures.
T-cell expansion
Cultures containing mature CD27
C
CD1a
¡ cells were expanded on irradiated allogenic feeder cells, consisting of a mixture of 40-Gy irradiated peripheral blood mononuclear cells and 50-Gy irradiated JY cells. Cells were cultured in IMDM (Gibco) with 10% FBS, supplemented with 2 mg/mL PHA (Oxoid, R30852801) or 10 ng of IL-7 and IL-15 (R&D Systems 247-ILB-025).
Flow cytometry and antibodies
Surface marker staining was performed in DPBS with 1% FBS using antibody concentration recommended by the supplier. Intracellular staining was performed following the supplier's protocol using Fix & Perm (BD Biosciences). Flow cytometric analysis was performed on the LSR II and cell sorting on the ARIA II (both BD Biosciences), both equipped with fur lasers. 
Flowcytometric determination of cytokine production
One hundred thousand culture expanded cells were stimulated by co-incubation with a cell line expressing the relevant antigen (LS174T, FM3 or Colo320) at 10 5 cells in 96-well flat-bottom plates. After 1 h, GolgiSTOP (BD Biosciences, cat# 51-2092KZ)) was added. After an additional 16 h of stimulation, the cells were harvested, permeabilized, labeled and analyzed for cytokine expression using TNF-PE-Cy7 (BD Biosciences, cat#557647), IFNg-PE (BD Biosciences, cat# 340452) and IL2-APC (BD Biosciences, cat# 554567).
Chromium release assay
Target cells were labeled with 51 Chromium, washed and used at different effector to target ratios. T2 cells were loaded for 2 h with the indicated peptide at a concentration of 10 mg/mL unless otherwise indicated before radioactive labeling. Effector cells consisted of culture expanded peripheral blood mononuclear cells or OP9-DL1 cultures. After a 4 h of co-incubation, supernatant was harvested and measured in a 1450 LSC & Luminescence Counter (Perkin Elmer). Specific lysis is calculated as followed: (experimental release ¡ spontaneous release)/(maximal release ¡ spontaneous release) £ 100%.
Real-time quantitative PCR (RT-qPCR)
Total RNA was prepared using the miRNeasy minikit (Qiagen). cDNA synthesis was performed by the Superscript First Strand Synthesis System for RT-PCR kit (Invitrogen). RT-qPCR with the SYBR Green I technology was performed using the LightCycler 480 SYBR Green I Master kit on a LightCycler 480 II (both Roche) according to the manufacturer's protocol. Used primers (Biolegio, Nijmegen, Netherlands) are listed in Table S1 . Results were analyzed using the ddCt method using actin as a reference gene.
CDR3a and CDR3b high-throughput sequencing
RNA was isolated from culture expanded HPC-derived wtTCR, TCR:z, TCR:28z, CAR:z, CAR:28z transgenic cell lines and from a PBMC-derived CAR:28z transgenic T cell line (10 5 -10 6 cells) with the RNeasy microkit (Qiagen) followed by template-switch anchored RT-PCR. 44 To each sample, Jurkat RNA was added for a total of 10% of the amount of RNA as an internal standard. A template-switch adaptor, AAGCAGTGGTATCAACGCAGAGTACATrGr GrG, was ligated at the 5 0 end of mRNA during cDNA generation using the Superscript II RT enzyme (Invitrogen). The cDNA product was purified using AMPure XP Beads (Agencourt). Then, PCR amplification (Lightcycler, Roche) was performed using a Ca specific primer (5 0 -GTCTCGTGGGCTCGGAGATGTG-TATAAGAGACAG TCTCAGCT GGTACACGGCAGGGT-CAGGGT-3 0 , adapter in italic) or a Cb specific primer (5 0 -GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG TGCT TCTGATGGCTCAAACACAGCGACCT-3 0 , adapter in italic) containing an adapter used in subsequent sequencing, and a primer complementary to the template-switch adapter (5 0 -TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG AAG-CAGTGGTATCAACGCAG-3 0 , adapter in italic) with the KAPA Real-Time Library Amplification Kit (Kapa Biosystems). After purification with AMPure XP Beads, an index PCR with Illumina sequencing adapters was performed using the Nextera XT Index Kit. This second PCR product was again purified with AMPure XP beads. High-throughput sequencing of the generated amplicon products containing the CDR3a or CDR3b sequences was performed on an Illumina MiSeq platform using the V2 300 kit, with 200 bp at the 3 0 end (read 2) and 100 bp at the 5 0 end (read 1) (at the GIGA center, University of Li ege, Belgium). CDR3 sequences were obtained by aligning the fastq files (read 2) with the MiXCR software version 1.7.1 45 with specified "-loci" parameter "TRA" and "TRB" for the alignment of CDR3a and CDR3b, respectively. Then, CDR3 sequences were assembled and exported. Spectratyping plots were generated via the routine PlotFancySpectratype of VDJTools version 1.0.7. 46 
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